{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:50:18Z","timestamp":1791931818676,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T00:00:00Z","timestamp":1395014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00280-014-2426-8","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T00:34:09Z","timestamp":1395102849000},"page":"951-960","source":"Crossref","is-referenced-by-count":85,"title":["A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors"],"prefix":"10.1007","volume":"73","author":[{"given":"Amita","family":"Patnaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wells A.","family":"Messersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos P.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralidhar","family":"Beeram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanitha","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mason Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter C.","family":"Darbonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer K.","family":"Brachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin D.","family":"Weekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,17]]},"reference":[{"key":"2426_CR1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-neuro-060909-152829","volume":"33","author":"SJ Tam","year":"2010","unstructured":"Tam SJ, Watts RJ (2010) Connecting vascular and nervous system development: angiogenesis and the blood-brain barrier. Annu Rev Neurosci 33:379\u2013408","journal-title":"Annu Rev Neurosci"},{"key":"2426_CR2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0092-8674(00)80534-6","volume":"90","author":"Z He","year":"1997","unstructured":"He Z, Tessier-Lavigne M (1997) Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 90:739\u2013751","journal-title":"Cell"},{"key":"2426_CR3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","volume":"92","author":"S Soker","year":"1998","unstructured":"Soker S, Takashima S, Quan H et al (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735\u2013745","journal-title":"Cell"},{"key":"2426_CR4","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1242\/dev.126.21.4895","volume":"126","author":"T Kawasaki","year":"1999","unstructured":"Kawasaki T, Kitsukawa T, Bekku Y (1999) A requirement for neuropilin-1 in embryonic vessel formation. Development 126:4895\u20134902","journal-title":"Development"},{"key":"2426_CR5","doi-asserted-by":"crossref","first-page":"24818","DOI":"10.1074\/jbc.M200730200","volume":"277","author":"R Mamluk","year":"2002","unstructured":"Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M et al (2002) Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 277:24818\u201324825","journal-title":"J Biol Chem"},{"key":"2426_CR6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.yexcr.2005.11.024","volume":"312","author":"DR Bielenberg","year":"2006","unstructured":"Bielenberg DR, Pettaway CA, Takashima S et al (2006) Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 312:584\u2013593","journal-title":"Exp Cell Res"},{"key":"2426_CR7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature10525","volume":"478","author":"B Beck","year":"2011","unstructured":"Beck B, Driessens G, Goossens S et al (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumors. Nature 478:399\u2013403","journal-title":"Nature"},{"key":"2426_CR8","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3390\/cancers3021899","volume":"3","author":"C Grandclement","year":"2011","unstructured":"Grandclement C, Borg C (2011) Neuropilins: a new target for cancer therapy. Cancers 3:1899\u20131928","journal-title":"Cancers"},{"key":"2426_CR9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jmb.2006.11.021","volume":"366","author":"W-C Liang","year":"2007","unstructured":"Liang W-C, Dennis MS, Stawicki S et al (2007) Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 366:815\u2013829","journal-title":"J Mol Biol"},{"key":"2426_CR10","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1007\/s11095-012-0781-x","volume":"29","author":"Y Xin","year":"2012","unstructured":"Xin Y, Bai S, Damico-Beyer LA et al (2012) Anti-neuropilin-1 (MRNP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans. Pharm Res 29:2512\u20132521","journal-title":"Pharm Res"},{"key":"2426_CR11","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1158\/1078-0432.CCR-12-1652","volume":"18","author":"Y Xin","year":"2012","unstructured":"Xin Y, Li J, Wu J et al (2012) Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel anti-angiogenesis agent, in two Phase I trials in patients with advanced solid tumors. Clin Cancer Res 18:6040\u20136048","journal-title":"Clin Cancer Res"},{"key":"2426_CR12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2006.10.018","volume":"11","author":"Q Pan","year":"2007","unstructured":"Pan Q, Chanthery Y, Liang W-C (2007) Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11:53\u201367","journal-title":"Cancer Cell"},{"key":"2426_CR13","doi-asserted-by":"crossref","unstructured":"Weekes CD1, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, Xin Y, Yu R, Shih LM, Xiang H, Brachmann RK, Patnaik A (2014) A Phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs. doi: 10.1007\/s10637-014-0071-z","DOI":"10.1007\/s10637-014-0071-z"},{"key":"2426_CR14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16\u201324","journal-title":"J Clin Oncol"},{"key":"2426_CR15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","volume":"5","author":"SE Deprimo","year":"2007","unstructured":"Deprimo SE, Bello CL, Smeraglia J et al (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5:32","journal-title":"J Transl Med"},{"key":"2426_CR16","unstructured":"Darbonne WC, Uppal H, Du X, et al (2014) Mechanism for platelet reduction in anti-neuropilin-1 (MNRP1685A)-treated patients in patients with advanced solid tumors (submitted)"},{"key":"2426_CR17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","volume":"19","author":"MS Gordon","year":"2001","unstructured":"Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843\u2013850","journal-title":"J Clin Oncol"},{"key":"2426_CR18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","volume":"62","author":"JF Lu","year":"2008","unstructured":"Lu JF, Bruno R, Eppler S et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779\u2013786","journal-title":"Cancer Chemother Pharmacol"},{"key":"2426_CR19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1074\/jbc.M508199200","volume":"2","author":"W-C Liang","year":"2006","unstructured":"Liang W-C, Wu X, Peale FV et al (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2:951\u2013961","journal-title":"J Biol Chem"},{"key":"2426_CR20","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1073\/pnas.0611492104","volume":"104","author":"H Gerber","year":"2007","unstructured":"Gerber H, Wu X, Yu L et al (2007) Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. PNAS 104:3478\u20133483","journal-title":"PNAS"},{"key":"2426_CR21","doi-asserted-by":"crossref","first-page":"F275","DOI":"10.1152\/ajprenal.2000.279.2.F275","volume":"279","author":"B Robert","year":"2000","unstructured":"Robert B, Zhao X, Abrahamson DR (2000) Coexpression of neuropilin-1, Flk1, and VEGF(164) in developing and mature mouse kidney glomeruli. Am J Physiol Renal Physiol 279:F275\u2013F282","journal-title":"Am J Physiol Renal Physiol"},{"key":"2426_CR22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.ki.5002726","volume":"73","author":"R Tapia","year":"2008","unstructured":"Tapia R, Guan F, Gershin I et al (2008) Semaphorin3a disrupts podocyte foot processes causing acute proteinuria. Kidney Int 73:733\u2013740","journal-title":"Kidney Int"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2426-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2426-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2426-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T22:55:25Z","timestamp":1648594525000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2426-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,17]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["2426"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2426-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,17]]}}}